© Reuters. BioDelivery Sciences settles Bunavail patent dispute with Teva
- BioDelivery Sciences (NASDAQ:BDSI) settles its patent infringement litigation with Teva Pharmaceutical Industries’ (NYSE:TEVA) U.S. unit related to BUNAVAIL (buprenorphine and naloxone). Teva had filed a marketing application seeking FDA approval for a generic version of the product.
- Under the terms of the settlement, BioDelivery grants Teva a non-exclusive license to sell a generic equivalent beginning July 23, 2028 or earlier under certain circumstances.